China (Mainland)
Estrogen receptor modulator raw material Raloxifene Hydrochloride CAS NO.82640-04-8
- FOB Price: USD: 50.00-50.00 /Metric Ton Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: T/T,MoneyGram
- Available Specifications:
10(10-20)Metric Ton
- Product Details
Keywords
- Raloxifene Hydrochloride
- Testosterone Base
- Testosterone Acetate
Quick Details
- ProName: Estrogen receptor modulator raw materi...
- CasNo: 82640-04-8
- Molecular Formula: C26H40O3
- Appearance: Light Yellow Powde
- Application: English name: Raloxifene hydrochloride...
- DeliveryTime: 7days
- PackAge: Foil bag
- ProductionCapacity: 50000 Kilogram/Week
- Purity: 99
- Storage: Placed in a cool place
- LimitNum: 1 Gram
- Moisture Content: 0.001
- Impurity: 0.001
Superiority
Raloxifene Hydrochloride
Product Name Raloxifene HCl Powder
CAS Registry Number 82640-04-8
Molecular Formula C28H28ClNO4S
Molecular Weight 510.05
Purity 99%
Grade Pharmaceutical Grade
Appearance Light Yellow Powde
Details
Raloxifene Hydrochloride
Product Name Raloxifene HCl Powder
CAS Registry Number 82640-04-8
Molecular Formula C28H28ClNO4S
Molecular Weight 510.05
Purity 99%
Grade Pharmaceutical Grade
Appearance Light Yellow Powde
1. Quick Detail:
Anti Estrogen Steroids Raloxifene Hydrochloride CAS 82640-04-8 Raloxifene HCL for Anti Cancer
2. Description:
English name: Raloxifene hydrochloride
English Synonyms: Raloxifene hydrochloride; Evista; Keoxifene hydrochloride; LY 156758; Raloxifene HCl;
CAS: 82640-04-8
Formula: C28H29NO4S
MW: 475.5992
Molecular Structure:
Density: 1.285g / cm3
Boiling point: 687.5 ° C at 760 mmHg
Flash Point: 369.6 ° C
Vapor Pressure: 1.56E-19mmHg at 25 ° C
Assay:99%
Appearance:light yellow powder
Use:antineoplastic
3. Applications:
May prevent or treat corticosteroid-induced bone loss .American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e.g., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.
Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.
Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial).No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.
